brightvision anti rabbit ap  (Vector Laboratories)

Journal: Genes & Diseases

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

doi: 10.1016/j.gendis.2025.101978

Figure Lengend Snippet: Specific IFN-γ and TNF-α release of T lymphocytes transduced with TIM-3-silenced HER2-specific chimeric antigen receptor (CAR) or HER2-specific CAR. (A, B) TIM-3-silenced CAR-T cells and control T cells were co-incubated with Galectin-9 + or Galectin-9 – SKOV3 tumor cells (E:T ratio 5:1 or 10:1). At 20 h after coculture, a specific enzyme-linked immunosorbent assay was used to analyze the supernatant for IFN-γ cytokine-release. Results were presented as mean ± standard deviation. (C, D) The detection of TNF-α in the same culture supernatant. Results were presented as mean ± standard deviation. ∗ P < 0.05 and ∗∗ P < 0.01.

Article Snippet: Human cervical cancer cell line HeLa, lentivirus packaging cell line HEK 293TD, and human ovarian cancer cell line SKOV3 were purchased from American Type Culture Collection (Manassas, Virginia, USA) and cultured in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, New York) supplemented with 10% heat-inactivated fetal bovine serum.

Techniques: Transduction, Control, Incubation, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Genes & Diseases

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

doi: 10.1016/j.gendis.2025.101978

Figure Lengend Snippet: TIM-3 silencing augmented the anti-tumor activity of chimeric antigen receptor-T (CAR-T) cells in vivo . 2 × 10 6 SKOV3 tumor cells expressing luciferase were intraperitoneally inoculated in a xenograft mouse model, and 7 days after inoculation, the 2 × 10 6 HER2-specific CAR-T kdTim-3 cells or CAR-T cells, or untreated T cells were intraperitoneally administered. (A, B) Tumor growth was monitored using an in vivo imaging system. (C) Survival curve of 80-day post-treatment. ∗ P < 0.05 and ∗∗ P < 0.01.

Article Snippet: Human cervical cancer cell line HeLa, lentivirus packaging cell line HEK 293TD, and human ovarian cancer cell line SKOV3 were purchased from American Type Culture Collection (Manassas, Virginia, USA) and cultured in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, New York) supplemented with 10% heat-inactivated fetal bovine serum.

Techniques: Activity Assay, In Vivo, Expressing, Luciferase, In Vivo Imaging

Journal: Oncology Letters

Article Title: LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches

doi: 10.3892/ol.2026.15671

Figure Lengend Snippet: Functional impact of LATS2 upregulation on LUAD/LUSC cell viability and apoptosis. (A) Baseline LATS2 expression comparison in A549 (LUAD), SK-MES-1 (LUSC) and Beas-2B (normal bronchial) cell lines. (B) Western blot validation of LATS2 protein overexpression post-transfection. (C) Transfection efficiency confirmation via fluorescence labeling (MOI=10; transfection rate=90.5 and 90% in LUAD and LUSC, respectively). Scale bar, 100 µm. (D) qPCR quantification of LATS2 mRNA induction post-transfection. (E) MTT assay evaluation of cell proliferation changes following LATS2 upregulation. (F) Flow cytometry analysis of apoptosis rate alterations after LATS2 upregulation. Data are presented as mean ± SD and all comparisons were conducted using independent samples t-test. *P<0.05, **P<0.01 and ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BC, blank control; NC, negative control; OE, overexpression; OD, optical density; MOI, multiplicity of infection; qPCR, quantitative PCR.

Article Snippet: The A549 and SK-MES-1 cells (Procell Life Science & Technology Co., Ltd.) were divided into BC (blank control (BC), negative control (NC) and overexpression (OE) groups.

Techniques: Functional Assay, Expressing, Comparison, Western Blot, Biomarker Discovery, Over Expression, Transfection, Fluorescence, Labeling, MTT Assay, Flow Cytometry, Control, Negative Control, Infection, Real-time Polymerase Chain Reaction

Journal: Oncology Letters

Article Title: LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches

doi: 10.3892/ol.2026.15671

Figure Lengend Snippet: Influence of LATS2 overexpression on LUAD and LUSC cell migration and invasion. (A) Wound healing assay in A549 cells. (B) Wound healing assay in SK-MES-1 cell lines. (C) Transwell assay evaluating altered invasive capacity of A549 and SK-MES-1 cells. (D) Comparison of cell migration rates. (E) Comparison of number of invading cells. Scale bar, 100 µm, **P<0.01 and ***P<0.001. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; LATS2, large tumor suppressor kinase 2; BC, blank control; NC, negative control; OE, overexpression.

Article Snippet: The A549 and SK-MES-1 cells (Procell Life Science & Technology Co., Ltd.) were divided into BC (blank control (BC), negative control (NC) and overexpression (OE) groups.

Techniques: Over Expression, Migration, Wound Healing Assay, Transwell Assay, Comparison, Control, Negative Control